reports
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections U...
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO) GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,274,830. The issued patent gives the Company protection for its method of delivering gaseous nitric oxide (gNO) to a p...
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndr...
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate for treating ASD in 2026 BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for autism and Alzheimer disorders, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and Drug ...
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Sc...
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer’s Disease BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and Alzheimer’s disease (AD)conditions, and a subsidiary of Beyond Air (NASDAQ: XAIR), is proud to announce the appointment of Nobel Prize laureate, Professor Dan...
Beyond Air Publishes Article in Annals of the American Thoracic Societ...
Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients’ Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home GARDEN CITY, N.Y., April 09, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the publication of its scientific article, “A Pilot Study to Assess the Effect of Intermittent In...
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demo...
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer’s disease, and a subsidiary of Beyond Air (NASDAQ: XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, ...
Beyond Air Announces Vanderbilt University Medical Center as First Lum...
Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO technology GARDEN CITY, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Vanderbilt Unive...
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an ...
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, includin...
- Jonathan Moreland
PSEC PROSPECT CAPITAL CORPORATION
OPK OPKO HEALTH INC.
FRPT FRESHPET INC
HRTG HERITAGE INSURANCE HOLDINGS INC.
CULP CULP INC.
MAC MACERICH COMPANY
ORN ORION GROUP HOLDINGS
TREE LENDINGTREE INC.
NKSH NATIONAL BANKSHARES INC.
FLWS 1-800-FLOWERS.COM CL A
MX MAGNACHIP SEMICONDUCTOR CORP.
TCPC BLACKROCK TCP CAPITAL CORP.
XAIR BEYOND AIR
CMPR CIMPRESS PLC
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
PRDO PERDOCEO EDUCATION CORP
FET FORUM ENERGY TECHNOLOGIES
SEAT VIVID SEATS INC.
FLNC FLUENCE ENERGY INC
BTMD HAYMAKER ACQUISITION CORP III
ECAT BLACKROCK ESG CAP ALLOCATION TR
ONL ORION OFFICE REIT INC
MLYS MINERALYS THERAPEUTICS INC
DK DELEK US HOLDINGS
CVI INC.
CUBA CVR ENERGY
SUNS INC.
AFCG THE HERZFELD CARIBBEAN BASIN FUND
INC.
SUNRISE REALTY TRUST
AFC GAMMA
INC.
AV’s Cutting-Edge One-Way Attack UAS Secures DIU Backing Under Project...
ARLINGTON, Va.--(BUSINESS WIRE)-- AeroVironment (AV), the leader in defense technology, has secured a contract with the Defense Innovation Unit (DIU) to accelerate the deployment of next-generation autonomous precision munitions. As part of its strategic expansion into a new sector of the multi-billion-dollar defense market, AV has been awarded an Other Transaction Authority (OT) award by the Defense Innovation Unit (DIU) as part of Project Artemis, an initiative launched to rapidly test and operationally evaluate long-range, one-way uncrewed aircraft systems (UAS) for the Department of Defen...
Beyond Air Announces Agreements Expanding Global Distribution of LungF...
Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH systems have been received for four countries GARDEN CITY, N.Y., March 11, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, ann...
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferen...
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the Roth 37th Annual Growth Stock Conference being held March 16-18, 2025 in Laguna, CA and the Jones Healthcare and Technology Innovation Confere...
AeroVironment Announces Fiscal 2025 Third Quarter Results
ARLINGTON, Va.--(BUSINESS WIRE)-- (“AeroVironment” or the “Company”) reported today financial results for the fiscal third quarter ended January 25, 2025. Third Quarter Highlights: Record funded backlog of $763.5 million as of January 25, 2025 Third quarter revenue of $167.6 million down 10% year-over-year Third quarter net loss of $(1.8) million and non-GAAP adjusted EBITDA of $21.8 million “We faced a number of short-term challenges in the third quarter, including the unprecedented high winds and fires in Southern California, which impacted our ability to meet our goals,” said Wahi...
AeroVironment, Inc. to Announce Third Quarter Fiscal Year 2025 Earning...
ARLINGTON, Va.--(BUSINESS WIRE)-- (NASDAQ: AVAV) will report its financial results for the third quarter of fiscal year 2025, which ended January 25, 2025, after the market closes on Wednesday, March 4, 2025. Management will host a conference call and live audio webcast at 4:30 p.m. Eastern Time that same day to discuss the results. The call will be led by Wahid Nawabi, AeroVironment’s chairman, president, and chief executive officer; Kevin P. McDonnell, senior vice president and chief financial officer; and Jonah Teeter-Balin, vice president of corporate development and investor relations. ...
AV Unveils JUMP 20-X: Revolutionizing Autonomous Maritime Operations w...
ABU DHABI, United Arab Emirates--(BUSINESS WIRE)-- AeroVironment (AV), a global leader in intelligent, multi-domain autonomous solutions, today announced the launch of the JUMP® 20-X, a next-generation, modular Group 3 uncrewed aircraft system (UAS) designed to meet the dynamic demands of modern warfare. Setting a new benchmark for autonomous maritime operations, the JUMP 20-X delivers unrivaled versatility, efficiency, and precision in contested and complex environments. This press release features multimedia. View the full release here: JUMP 20-X executes a precision landing on a rapidly mo...
AV Expands U.S. Manufacturing in Salt Lake City, Utah with FreedomWerx...
ARLINGTON, Va.--(BUSINESS WIRE)-- AeroVironment (AV), the leader in autonomous and intelligent multi-domain systems, today announced the establishment of FreedomWerx, a state-of-the-art advanced manufacturing facility in Salt Lake City, Utah. This press release features multimedia. View the full release here: New 200,000-square-foot facility will expand production of AV’s battle-proven Loitering Munitions Systems (Photo: AV) As part of AV’s distributed production strategy, FreedomWerx strengthens the company’s capacity to ensure uninterrupted delivery of precision-strike autonomous systems to...
Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Pr...
Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH® in Europe and Market Authorization in Australia; international shipments to commence later this year Conference call at 4:30 p.m. ET today, February 10th GARDEN CITY, New York, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessi...
AV’s JUMP 20 Selected by Danish Defence Acquisition and Logistics Orga...
ARLINGTON, Va.--(BUSINESS WIRE)-- AeroVironment (AV), through its wholly owned subsidiary Arcturus UAV, has been awarded a contract by the Danish Defence Acquisition and Logistics Organisation (DALO) with a contract ceiling value of $181 million to deliver the JUMP® 20 medium uncrewed aircraft system (UAS) to the Danish Armed Forces. This 10-year program of record will equip the Danish Army with JUMP 20 systems to enhance intelligence, surveillance, and reconnaissance (ISR) operations, reinforcing AV’s position as a global leader in advanced autonomous solutions. This press release features m...
Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance w...
Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement GARDEN CITY, N.Y., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced it received a notification from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has been granted an additional 180-day compliance period, or until August 4, 2025 to regain compliance with Nasdaq’s...
AV Secures $288 Million Delivery Order on $990 Million Contract with U...
ARLINGTON, Va.--(BUSINESS WIRE)-- AeroVironment (AV), a global leader in intelligent, multi-domain robotic systems, today announced it has been awarded its third delivery order totaling $288 million of Switchblade® loitering munition systems as part of U.S. Army’s Directed Requirement (DR) for Lethal Unmanned Systems (LUS). The delivery is part of a 5-year Indefinite Delivery, Indefinite Quantity (IDIQ) contract from Army Contracting Command-Aberdeen Proving Ground, with a contract ceiling value of $990 million, announced in August 2024. This press release features multimedia. View the full r...
Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conf...
Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the fiscal third quarter 2025 ended December 31, 2024 on Monday, February 10, 2025 after the market closes. Conference Call & WebcastMonday, February 10th @ 4:30 PM ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.